{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/115658"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/115658","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"The development of 3-(4-hydroxyphenyl)indoline-2-ones and other strategies for the treatment of cancer","abstract":"Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2024-05-01","abstract_html":"Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2024-05-01","abstract_has_math":false,"creators":["Boudreau, Matthew W."],"institution":"University of Illinois at Urbana-Champaign","degree_name":"Ph.D.","degree_level":"Dissertation","degree_discipline":"Chemistry","degree_department":null,"school":null,"contributors":["Hergenrother, Paul J","Burke, Martin D","Mitchell, Douglas A","Fan, Timothy M"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2022,"date_issued":"2022-05","date_published":"2022-05","updated_at":"2026-07-22T22:24:54Z","subjects":["cancer","drug development"],"languages":["en","eng"],"rights":["Copyright 2022 Matthew W. Boudreau"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2142/115658","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Hergenrother, Paul J","Burke, Martin D","Mitchell, Douglas A","Fan, Timothy M"]},{"key":"dc:creator","label":"Author","values":["Boudreau, Matthew W."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2022-05","2022-02-28"]},{"key":"dc:type","label":"Dc Type","values":["text","Thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["cancer","drug development"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en","eng"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2022 Matthew W. Boudreau"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://hdl.handle.net/2142/115658"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2024-05-01","The student, Matthew Boudreau, accepted the attached license on 2022-02-10 at 16:41.","The student, Matthew Boudreau, submitted this Dissertation for approval on 2022-02-10 at 16:48.","This Dissertation was approved for publication on 2022-02-28 at 09:12.","DSpace SAF Submission Ingestion Package generated from Vireo submission #17499 on 2022-11-11 at 12:18:14","Over the past century, our ability to develop new targeted anticancer strategies has ushered in a new era in cancer treatment that has greatly evolved from the radical surgery and highly toxic campaigns of the past. Often common in anticancer small molecule development is a complex history outlining how chemical matter was first identified, derivatized, and utilized to ultimately arrive at exciting molecules for drug development. Herein, the history and our current journey of one such developing anticancer scaffold, the 3-(4-hydroxyphenyl)indoline-2-ones, is reviewed. With humble beginnings in 19th century Bavaria to recent interest in its tumor eradication of drug-resistant breast cancer, 3-(4-hydroxyphenyl)indoline-2-ones are an intriguing anticancer pharmacophore. Specifically, we describe our discovery of ErSO, a 3-(4-hydroxyphenyl)indoline-2-one that induces estrogen receptor alpha-positive (ERα)-dependent death of breast cancer cells through a mechanism distinct from clinically approved ERα drugs, namely hyperactivation of the anticipatory unfolded protein response (a-UPR). ErSO has remarkable activity in multiple ERα-positive tumor models, with several examples of complete tumor eradication without recurrence. While ErSO has tremendous promise as a new drug to target ERα-positive breast cancer, we also report herein the discovery of second-generation derivatives, ErSO-DFP and ErSO-TFPy, which have even more promising targeted anticancer activities. Unrelated to 3-(4-hydroxyphenyl)indoline-2-ones research, a variety of other ongoing anticancer projects being developed in the Hergenrother laboratory (PAC-1 and IB-DNQ) are described."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["The development of 3-(4-hydroxyphenyl)indoline-2-ones and other strategies for the treatment of cancer"]}]}],"canonical_facts":{"dc:contributor":["Hergenrother, Paul J","Burke, Martin D","Mitchell, Douglas A","Fan, Timothy M"],"dc:creator":["Boudreau, Matthew W."],"dc:date":["2022-05","2022-02-28"],"dc:description":["Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2024-05-01","The student, Matthew Boudreau, accepted the attached license on 2022-02-10 at 16:41.","The student, Matthew Boudreau, submitted this Dissertation for approval on 2022-02-10 at 16:48.","This Dissertation was approved for publication on 2022-02-28 at 09:12.","DSpace SAF Submission Ingestion Package generated from Vireo submission #17499 on 2022-11-11 at 12:18:14","Over the past century, our ability to develop new targeted anticancer strategies has ushered in a new era in cancer treatment that has greatly evolved from the radical surgery and highly toxic campaigns of the past. Often common in anticancer small molecule development is a complex history outlining how chemical matter was first identified, derivatized, and utilized to ultimately arrive at exciting molecules for drug development. Herein, the history and our current journey of one such developing anticancer scaffold, the 3-(4-hydroxyphenyl)indoline-2-ones, is reviewed. With humble beginnings in 19th century Bavaria to recent interest in its tumor eradication of drug-resistant breast cancer, 3-(4-hydroxyphenyl)indoline-2-ones are an intriguing anticancer pharmacophore. Specifically, we describe our discovery of ErSO, a 3-(4-hydroxyphenyl)indoline-2-one that induces estrogen receptor alpha-positive (ERα)-dependent death of breast cancer cells through a mechanism distinct from clinically approved ERα drugs, namely hyperactivation of the anticipatory unfolded protein response (a-UPR). ErSO has remarkable activity in multiple ERα-positive tumor models, with several examples of complete tumor eradication without recurrence. While ErSO has tremendous promise as a new drug to target ERα-positive breast cancer, we also report herein the discovery of second-generation derivatives, ErSO-DFP and ErSO-TFPy, which have even more promising targeted anticancer activities. Unrelated to 3-(4-hydroxyphenyl)indoline-2-ones research, a variety of other ongoing anticancer projects being developed in the Hergenrother laboratory (PAC-1 and IB-DNQ) are described."],"dc:format":["application/pdf"],"dc:identifier":["https://hdl.handle.net/2142/115658"],"dc:language":["en","eng"],"dc:rights":["Copyright 2022 Matthew W. Boudreau"],"dc:subject":["cancer","drug development"],"dc:title":["The development of 3-(4-hydroxyphenyl)indoline-2-ones and other strategies for the treatment of cancer"],"dc:type":["text","Thesis"],"thesis:degree_discipline":["Chemistry"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Ph.D."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:24:54Z"}